Statement: the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis. smoothened antagonist is any agent that is an antagonist at the smoothened (smo) receptor.
Primary_evidence: Outcome Measurement:    Local Control Using Ipsilateral Breast Tumor Recurrence Rates   [Not Specified]   Time frame: 2 years after treatment completion Results 1:    Arm/Group Title: Accelerated Partial Breast Brachytherapy   Arm/Group Description: Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.   Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.   Overall Number of Participants Analyzed: 151   Measure Type: Number   Unit of Measure: percentage of participants  .7